What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ECT204 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the ECT204 transgene.”In the company’s words, NCT04864054 on ClinicalTrials.gov
- Main trialPhase 1/2
- “This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, prior systemic therapy.”In the company’s words, NCT04864054 on ClinicalTrials.gov
Other drugs for Hepatocellular Carcinoma
- CadonilimabAkeso · Phase 3
- DurvalumabAstraZeneca · Phase 3
- TremelimumabAstraZeneca · Phase 3
- BudigalimabAbbVie · Phase 2/3
- LivmoniplimabAbbVie · Phase 2/3
- BGB-B2033BeOne Medicines (BeiGene) · Phase 3
Coming up1
- 31 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Dec 2027 | GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026